---
title: "Valneva Sets May 13 Date to Present First-Quarter 2026 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285243089.md"
description: "Valneva SE, a France-based specialty vaccine maker, will present its first-quarter 2026 results on May 13, 2026, at 3 p.m. CET/9 a.m. ET. The event will be streamed live and archived on the company’s website, providing insights into its commercial performance and pipeline progress. Valneva focuses on targeted vaccines for infectious diseases and has a partnership with Pfizer for a Lyme disease vaccine. The latest analyst rating for VALN stock is a Sell with a $4.90 price target, reflecting concerns over financial performance and market sentiment."
datetime: "2026-05-05T16:27:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285243089.md)
  - [en](https://longbridge.com/en/news/285243089.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285243089.md)
---

# Valneva Sets May 13 Date to Present First-Quarter 2026 Results

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Valneva ( (VALN) ) has issued an update.

Valneva SE, a France-based specialty vaccine maker listed on Nasdaq and Euronext Paris, focuses on targeted prophylactic vaccines for infectious diseases, funding its pipeline through revenues from three marketed travel vaccines. Its R&D portfolio includes an advanced Lyme disease vaccine candidate partnered with Pfizer and what it describes as the world’s most clinically advanced Shigella vaccine candidate, alongside other programs addressing global public health threats.

On May 5, 2026, Valneva announced it would report first-quarter 2026 consolidated financial results on May 13, 2026 and host a live webcast at 3 p.m. CET/9 a.m. ET to discuss the numbers and provide a business update. The event, to be streamed and archived via the company’s website, signals upcoming visibility into the group’s commercial performance and pipeline progress, information closely watched by investors given its partner-driven and innovation-focused growth strategy.

The most recent analyst rating on (VALN) stock is a Sell with a $4.90 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

**Spark’s Take on VALN Stock**

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

The score is held down primarily by weak financial performance (large losses, negative free cash flow, and elevated leverage) and bearish technical momentum (price below major moving averages with negative MACD). The latest earnings call adds some support via liquidity/cash-burn improvement and pipeline catalysts, but guidance implies a 2026 revenue step-down and key upside (Lyme) remains timing-dependent. Valuation is difficult to assess with a negative P/E and no dividend yield provided.

To see Spark’s full report on VALN stock, click here.

**More about Valneva**

Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The France-based group leverages multiple vaccine modalities and currently markets three proprietary travel vaccines, while advancing a pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development with Pfizer and a leading Shigella vaccine candidate.

**Average Trading Volume:** 88,659

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $453.5M

For an in-depth examination of VALN stock, go to TipRanks’ Overview page.

### Related Stocks

- [VALN.US](https://longbridge.com/en/quote/VALN.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug](https://longbridge.com/en/news/285837287.md)
- [Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone](https://longbridge.com/en/news/284848448.md)
- [Fact Check: Le vaccin contre la COVID-19 de Pfizer n'est pas connu pour déclencher une infection à hantavirus](https://longbridge.com/en/news/286224755.md)
- [Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position](https://longbridge.com/en/news/285840890.md)
- [Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News](https://longbridge.com/en/news/286109610.md)